Document is current
Any future updates will be listed below
-
Authors
Edwards, Kristina R.
Malhi, Harman
Schmidt, Karina
Davis, Amelia R. https://orcid.org/0000-0002-6983-3567
Homad, Leah J.
Warner, Nikole L. https://orcid.org/0000-0002-2307-5529
Chhan, Crystal B.
Scharffenberger, Samuel C. https://orcid.org/0000-0001-5905-8862
Gaffney, Karen
Hinkley, Troy https://orcid.org/0000-0003-4833-0255
Potchen, Nicole B. https://orcid.org/0000-0003-0699-8863
Wang, Jing Yang
Price, Jason
McElrath, M. Juliana
Olson, James
King, Neil P. https://orcid.org/0000-0002-2978-4692
Lund, Jennifer M.
Moodie, Zoe https://orcid.org/0000-0001-8701-2001
Erasmus, Jesse H. https://orcid.org/0000-0003-1612-2697
McGuire, Andrew T. https://orcid.org/0000-0003-1841-6859
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI147846, 5T32AI007509)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA285227)
- License Information
-
More Information
Article History
Received: 6 April 2024
Accepted: 10 June 2024
First Online: 26 June 2024
Competing interests
: A.T.M., J.P. and J.O. are co-inventors on US patent application no. 18/458,108 pertaining to the gH/gL- cTRP(6)ss and gH/gL-IMX313 sequences. J.H.E. has equity interest in HDT Bio and is a co-inventor on U.S. patent application no. 62/993,307 “Compositions and methods for delivery of RNA” pertaining to the LION formulation. A.T.M. and J.H.E. are co-inventors on US patent applications 63/558,943 and 63/560,834 pertaining to vaccines against gamma herpesviruses.” All other authors declare no competing interests.
